Amy R. McDowell1, Stephen J. Wastling1,2, Lara Cristiano3, Jasper M. Morrow1, Matthew R.B. Evans4, Christopher D.J. Sinclair1, Pedro M. Machado1, Michael Hanna1, Mary M. Reilly1, Tarek Yousry1, and John S. Thornton1
1MRC Centre for Neuromuscular Diseases, UCL Queen Square Institute of Neurology, London, United Kingdom, 2Lysholm Department of Neuroradiology, National Hospital for Neurology and Neurosurgery, London, United Kingdom, 3Department of Pediatric Neurology and Radiology, Fondazione Policlinico Universitario, Rome, Italy, 4St Thomas Hospital, London, United Kingdom
Synopsis
Muscle T2 and fat-fraction are two promising
metrics for sensitive measures of early disease-related changes in muscle for
use in clinical trials. However, fat has a longer T2 than water in muscle and masks underlying
increases in water T2 due to muscle oedema. The IDEAL-CPMG sequence with
appropriate image-data processing produces a T2-water map uncontaminated by the
fat signal. This sequence was acquired in healthy volunteers and two different muscular
dystrophy disease types. It was found that elevated T2-water may be a
predictor of later progression to fatty-atrophy in muscle, supporting the value of
future longitudinal studies to test this.
Introduction
Muscle oedema
and fat infiltration are characteristics of a range of neuromuscular diseases.
Novel therapies for these conditions could be expedited if more sensitive
measures of early disease-related changes in muscle could be found for use in
clinical trials. The disease processes involve changes in intramuscular water
and fat distributions; muscle T2 and fat-fraction are two promising
metrics. Conventional multi-echo T2 mapping of the gluteus maximus
muscle has been shown to be a quantitative and objective measure of disease
severity in boys with Duchenne’s
Muscular Dystrophy (DMD)1.
The IDEAL‐CPMG pulse sequence2 combines IDEAL fat–water chemical
shift separation with CPMG multi‐echo spin‐echo measurement of T2, and
hence yields separate measurements of the T2 of water and fat in a
single acquisition. Fat has a longer T2 than water in muscle and conventional
MRI relaxometry masks any underlying increases in water T2 due to muscle
oedema. The IDEAL-CPMG sequence with appropriate image-data processing produces
a T2-water map uncontaminated by the fat signal.
The IDEAL-CPMG sequence has been
previously validated in phantoms, and used in healthy volunteers, boys with DMD3, hypokalemic periodic paralysis4 and showed muscle-specific
patterns of fat infiltration and oedema in a single participant with Inclusion Body Myositis
(IBM)2. We extend this work with data
from two participant groups,
one with IBM and a second with the inherited neuropathy Charcot-Marie-Tooth
disease Type 1A (CMT1A), to examine the potential of IDEAL-CPMG in monitoring
large patient cohorts in longitudinal clinical trials. IBM is a primary muscle
disease causing inflammation and damage in active areas, resulting in final fat
replacement and atrophy of the muscle; whereas in CMT1A disease, atrophy and
fat infiltration are sequelae of muscle denervation. The differing causes and
disease progression present two different pathological patterns on MRI. We
present here IDEAL-CPMG T2-water maps with comparison to standard Dixon Fat
Fraction (Dixon-FF%) maps in these two diseases.Methods
These data were acquired in the
context of a five-year longitudinal observational study, where the participant
assessment, recruitment and inclusion criteria has been previously described in
Morrow et al5. Eight participants with IBM (8
male, 68.0±5.7 years, range 61.8-80.3 years),
nine participants with CMT1A (4 male, 47.2±15.2 years,
range 24.2-71.5 years) and nine healthy volunteers (HV) with no known muscle pathology
(6 male, 57.8±14.3 years, range 25.4-73.9 years)
were scanned with the IDEAL-CPMG sequence at a single timepoint within the
larger study.
Image acquisition included
IDEAL-CMPG2 (16 echoes, first echo 12ms, 12ms
increments, TR 3000ms, 2.1x2.1mm pixel size, 5mm slice thickness) and 3-point
Dixon6 (TE 3.45, 4.6, 5.75ms, TR 100ms,
4 averages, 0.8x0.8mm pixel size, 10mm slice thickness). The IDEAL-CMPG data were processed
using an in-house MATLAB (https://uk.mathworks.com/products/matlab.html) script
as detailed in Janiczek et al.2. 3-point Dixon data were processed using an in-house
Python (http://www.python.org) script based
on Glover et al.7. A trained observer manually segmented the calf muscles on the shortest
echo time (TE = 3.45ms) high-resolution gradient-echo image using the ITK‐SNAP
(http://www.itksnap.org) software. These regions-of-interest (ROIs) were
transformed into the space of the IDEAL-CPMG images using FSL (https://fsl.fmrib.ox.ac.uk/fsl/fslwiki/) and overlaid on T2-water and Dixon-FF%
maps for data extraction.Results and Discussion
Figure 1 shows
example T2-water and Dixon-FF% images in a HV, a person with CMT1A and a person
with IBM. The ROIs are shown in colour in the centre. The HV shows maps uniform
in the muscle as expected. The person with CMT1A has corresponding pathological
changes in the Dixon-FF% and T2-water maps, but the person with IBM shows
increased T2-water in areas (red arrows) that do not have corresponding increases
in the Dixon-FF%, due to inflammation and active disease in these areas.
Figure 2 shows
the T2-water results for each muscle group in the calf separated for IBM, CMT1A
and HV. There was a narrow normal T2-water range for all HV across all muscle
groups centred on 31.7ms (SD±2.4). At the group level, elevated T2-water was seen
with anatomical distributions differing between the two patient groups but consistently
higher in the IBM patients. Four of the nine CMT1A subjects had no discernible
fat infiltration on the Dixon images and no corresponding increase in T2-water,
contributing to the larger spread of values in the CMT1A group. Figure 3 shows
the corresponding Dixon-FF% results for comparison.Conclusion
Quantitative IDEAL-CPMG
T2-water maps were successfully obtained in all participants. T2-water maps
showed raised signal in areas of oedema, and in 2 participants with IBM there
was evidence of increased T2-water with no marked fat-fraction increase. This
suggests that elevated T2-water may be a predictor of later progression to
fatty-atrophy in IBM, supporting the value of future longitudinal studies to
test this hypothesis. As IBM has a greater inflammatory component to the
disease than CMT1A, this predictor may not be seen in CMT1A, but this would
require investigation in a larger cohort. Alternative sequences such as fat suppressed
T2w-STIR may not be as sensitive to changes in muscle water load, as the
contrast involves both muscle hypointensity due to fat infiltration and
hyperintensity due to elevated T2 value, which may tend to cancel.
Quantitative T2 mapping with water-fat separated methods such as
IDEAL-CPMG provides objective measures for comparison with normative data and
longitudinally over several time points.Acknowledgements
This work was supported by the MRC
(grant numbers G0601943 2008–2013 and MR/K000608/1 2013–2018). We gratefully acknowledge
the capital and research support of the NIHR University College London
Hospitals Biomedical Research Centre (2008–2013 and
2013–2018). We thank patient
organisations including CMT UK and the Myositis Support
Group who made patients aware of
this study. We thank all patients who took part in this study.References
1. Kim
HK, Laor T, Horn PS, Racadio JM, Wong B, Dardzinski BJ. T2 mapping in Duchenne
muscular dystrophy: distribution of disease activity and correlation with
clinical assessments. Radiology. 2010;255(3):899-908.
2. Janiczek
RL, Gambarota G, Sinclair CD, et al. Simultaneous T(2) and lipid quantitation
using IDEAL-CPMG. Magnetic resonance in
medicine. 2011;66(5):1293-1302.
3. Mankodi
A, Azzabou N, Bulea T, et al. Skeletal muscle water T2 as a biomarker of
disease status and exercise effects in patients with Duchenne muscular
dystrophy. Neuromuscul Disord. 2017;27(8):705-714.
4. Sinclair
CD, Morrow JM, Janiczek RL, et al. Stability and sensitivity of water T2
obtained with IDEAL-CPMG in healthy and fat-infiltrated skeletal muscle. NMR in biomedicine. 2016;29(12):1800-1812.
5. Morrow
JM, Sinclair CD, Fischmann A, et al. MRI biomarker assessment of neuromuscular
disease progression: a prospective observational cohort study. Lancet neurology. 2016;15(1):65-77.
6. Burakiewicz
J, Sinclair CDJ, Fischer D, Walter GA, Kan HE, Hollingsworth KG. Quantifying
fat replacement of muscle by quantitative MRI in muscular dystrophy. Journal of neurology. 2017;264(10):2053-2067.
7. Glover
GH, Schneider E. Three-point Dixon technique for true water/fat decomposition
with B0 inhomogeneity correction. Magnetic
resonance in medicine. 1991;18(2):371-383.